Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02999698|
Recruitment Status : Unknown
Verified December 2016 by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau.
Recruitment status was: Not yet recruiting
First Posted : December 21, 2016
Last Update Posted : December 22, 2016
|Condition or disease||Intervention/treatment|
|Psoriasis Hidradenitis||Other: Observational|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||A Comparative Retrospective Study Between Patients With Hidradenitis vs Patients With Psoriasis: Psychological Impact|
|Study Start Date :||February 2017|
|Estimated Primary Completion Date :||April 2017|
|Estimated Study Completion Date :||June 2017|
Patients with psoriasis complete the questionnaires for psychological impact.
Hidradenitis Suppurativa Group
Patients with hidradenitis suppurativa complete the questionnaires for psychological impact.
- Dermatology Quality of Life Index (DLQI) [ Time Frame: 1 day ]The Dermatology Life Quality Index or DLQI, developed in 1994, was the first dermatology-specific Quality of Life instrument. It is a simple 10-question validated questionnaire that has been used in over 40 different skin conditions in over 80 countries and is available in over 90 languages. Its use has been described in over 1000 publications including many multinational studies. The DLQI is the most frequently used instrument in studies of randomised controlled trials in dermatology.
- Hospital Anxiety and Depression Scale (HADS) [ Time Frame: 1 day ]Hospital Anxiety and Depression Scale (HADS) was originally developed by Zigmond and Snaith (1983) and is commonly used by doctors to determine the levels of anxiety and depression that a patient is experiencing. The HADS is a fourteen item scale that generates ordinal data. Seven of the items relate to anxiety and seven relate to depression.
- Perceived Stress Scale (PSS) [ Time Frame: 1 day ]Perceived Stress Scale (PSS) was originally developed by Cohen (1983) and this scale is a self-report instrument that evaluates the level of stress perceived during the last month. The scale consists of 14 items with a response format of a five-point scale (0 = never, 1 = almost never, 2 = Every now and then, 3 = often, 4 = very often). The score obtained indicates that a higher score corresponds to a higher level of perceived stress.
- The Holmes and Rahe stress scale [ Time Frame: 1 day ]The Holmes and Rahe stress scale is a list of 43 stressful life events that can contribute to illness.
- Psoriasis Area Severity Index (PASI) [ Time Frame: 1 day ]The Psoriasis Area Severity Index (PASI) is an index used to express the severity of psoriasis. It combines the severity (erythema, induration and desquamation) and percentage of affected area.
- Static Physician's Global Assessment (sPGA) [ Time Frame: 1 day ]The PGA is a 5 point ordinal rating ranging from "clear" to "very severe psoriasis".
- Hurley's staging system [ Time Frame: 1 day ]Hurley separated patients into three groups based largely on the presence and extent of cicatrization and sinuses. It has been used as a basis for clinical trials in the past and is a useful basis to approach therapy for patients. These three stages are based on Hurley's staging system, which is simple and relies on the subjective extent of the diseased tissue the patient has. Hurley's three stages of hidradenitis suppurativa.
- Hidradenitis Suppurativa - Physician Global Assessment (HS-PGA) [ Time Frame: 1 day ]The six-point Physician Global Assessment (PGA) ranges from clear to very severe. It is used in clinical trials to measure clinical improvement in inflammatory nodules, abscesses and draining fistulae
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02999698
|Contact: Esther Margarit de Miguel, Mscemail@example.com|
|Contact: Eva Vilarrasa Rull, Dr.||+firstname.lastname@example.org|
|Principal Investigator:||Esther Margarit de Miguel, Msc||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|
|Study Director:||Antoni Font Guiteras, PhD||Universitat Autonoma de Barcelona|